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Abstract
Current algorithms for assessing risk of atherosclerotic cardiovascular disease (ASCVD) and, in particular, the
reliance on low-density lipoprotein (LDL) cholesterol in conditions where this measurement is discordant with
apoB and LDL-particle concentrations fail to identify a sizeable part of the population at high risk for adverse
cardiovascular events. This results in missed opportunities for ASCVD prevention, most notably in those with
metabolic syndrome, prediabetes, and diabetes. There is substantial evidence that accumulation of ectopic fat
and associated metabolic traits are markers for and pathogenic components of high-risk atherosclerosis. Con-
ceptually, the subset of advanced lesions in high-risk atherosclerosis that triggers vascular complications is
closely related to a set of coordinated high-risk traits clustering around a distinct metabolic phenotype. A key
feature of this phenotype is accumulation of ectopic fat, which, coupled with age-related muscle loss, creates a
milieu conducive for the development of ASCVD: atherogenic dyslipidemia, nonresolving inflammation, en-
dothelial dysfunction, hyperinsulinemia, and impaired fibrinolysis. Sustained vascular inflammation, a hallmark
of high-risk atherosclerosis, impairs plaque stabilization in this phenotype. This review describes how metabolic
and inflammatory processes that are promoted in large measure by ectopic adiposity, as opposed to subcuta-
neous adipose tissue, relate to the pathogenesis of high-risk atherosclerosis. Clinical biomarkers indicative of
these processes provide incremental information to standard risk factor algorithms and advanced lipid testing
identifies atherogenic lipoprotein patterns that are below the discrimination level of standard lipid testing. This
has the potential to enable improved identification of high-risk patients who are candidates for therapeutic
interventions aimed at prevention of ASCVD.
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Despite ongoing advances in cardiovascular medicine,acute complications of atherosclerosis remain the lead-
ing causes of death worldwide.1 Of concern, common ap-
proaches relying on clustered risk factors and surrogate
biomarkers fail to identify a sizeable proportion of indi-
viduals at high risk for cardiovascular events.2 Furthermore,
despite management of low-density lipoprotein cholesterol
(LDL-C) and other conventional risk factors, significant
residual risk remains.
One explanation for this observation is the high preva-
lence of individuals with metabolic disorders where plasma
LDL-C and atherogenic lipoprotein particle concentration,
as assessed by apoB or direct particle measurement, become
discordant, rendering LDL-C less predictive of atheroscle-
rotic cardiovascular disease (ASCVD) events.3 This results
in missed opportunities for prevention and intensification of
lifestyle intervention and/or pharmacotherapy in the sub-
group of the population with metabolic syndrome (MetS),
prediabetes, and diabetes, which is at highest risk for vas-
cular complications. Thus, assessment of adjunctive bio-
markers for the presence and severity of subclinical ASCVD
is of utmost importance for taking appropriate measures to
prevent adverse clinical outcomes and reduce the associated
economic burden of this disease.
This review discusses the biochemical principles under-
lying high-risk atherosclerosis within the conceptual frame-
work of the phenotype characterized by excess ectopic fat.
It furthermore provides perspective on clinical biomarkers
indicative of this high-risk metabolic condition, which may
add incremental information to standard risk factor algo-
rithms for detection of high-risk patients who are candi-




An integrative view on atherosclerosis
Atherosclerosis is a lifelong process, and it progresses at
various rates depending on genetic and nongenetic factors.4
It is initiated by the penetration and retention of apoB-
containing lipoproteins within the subendothelial intima of
arteries. This process is gradient driven, providing biological
plausibility for the concept that the number of apoB-
containing lipoprotein particles, not their aggregate choles-
terol content (LDL-C), more closely tracks with risk.5–7
It is, however, worth noting that numerous factors modify
the causality of lipoprotein-driven disease risk in ASCVD.8
High-risk atherosclerosis is closely associated with a clus-
ter of metabolic and inflammatory features of a phenotype
characterized by an increase of ectopic body fat.9,10 Figure 1
depicts a conceptual framework of how the accumulation of
dysfunctional, ectopic fat in the abdominal cavity (visceral
fat) and in organs (pericardium, liver, pancreas, and skeletal
muscle)—in particular if accompanied by sarcopenia11,12—
contributes to a proatherogenic and procoagulatory state9,10,13
and drives high-risk atherosclerosis through multiorgan/tissue
involvement. Figure 1 furthermore maps the links between
each of the elements within this framework.
The role of body composition in ASCVD
Body composition, in particular accumulation of dys-
functional adipose tissue (AT)9,10 and loss of skeletal
muscle,11,12 is at the core of a cluster of local and systemic
pathophysiological changes that have been linked to high-
risk atherosclerosis (Fig. 1A, B).
As depicted in Figure 1, excess hepatic fat production
(i.e., de novo lipogenesis) may be an early common path-
way of non-alcoholic fatty liver disease (NAFLD), athero-
genic dyslipidemia, pancreatic b cell dysfunction, insulin
resistance, and associated ASCVD risk in the high-risk
phenotype.10,14
AT secretome. While subcutaneous AT is largely neutral,
or in the case of lower body AT even protective with respect
to cardiovascular risk,15 expansion of visceral and/or ectopic
dysfunctional AT is closely linked to poor cardiometabolic
health and MetS9,16 (Fig. 1A). Factors that promote AT
dysfunction are chronic positive energy balance in conjunc-
tion with biochemical stressors, including physical inactiv-
ity,9 poor diet quality,9 active/passive exposure to cigarette
smoke,17 and sleep deprivation.18 Free fatty acid-induced
cellular stress causes remodeling of AT and encompasses
a set of changes, including AT inflammation and altered
secretome and modulation of the browning phenotype.
Dysfunctional AT is characterized by an infiltration of
macrophages and lymphocytes, and an increased abundance
of senescent cells. These cells release fatty acids and
proinflammatory and chemotactic compounds, which is re-
ferred to as a senescence-associated secretory phenotype. In
a vicious cycle, this promotes ectopic fat accumulation and
contributes to chronic inflammation, metabolic disturbances,
sarcopenia, and accelerated cardiovascular aging.19 Epi-
cardial AT (Fig. 1A1) is regarded as a paracrine transducer
of the adverse effects of systemic inflammation and meta-
bolic dysregulation on adjacent tissues, such as the under-
lying coronary arteries, and has accordingly been linked to
arrhythmia/atrial fibrillation, accelerated coronary athero-
sclerosis, and left ventricular diastolic dysfunction.20 Hepatic
fat accumulation/NAFLD (Fig. 1A2) causally contributes to
atherogenic dyslipidemia [high plasma triglyceride and re-
duced high-density lipoprotein cholesterol (HDL-C)]. In-
creased hepatic de novo lipogenesis is furthermore associated
with higher hepatic palmitic acid (C16:0) flux and enrich-
ment of palmitic acid in very low-density lipoprotein parti-
cles (VLDL-P).14 Palmitic acid contributes to vascular
inflammation through dimerization and activation of toll-like
receptor (TLR) 2/4 as explained further below.21 These
mechanisms provide some plausibility for the observation
that NAFLD is closely linked to subclinical atherosclero-
sis.22 Pancreatic fat (Fig. 1A3) has been linked to b cell
dysfunction23 and concomitant postprandial and fasting hy-
perglycemia. Chronically elevated serum glucose levels,
and postprandial glucose spikes in particular, result in sym-
pathetic hyperactivity and the formation of advanced gly-
cation end products (AGEs). AGE, through interaction with
receptor for AGEs, activate proinflammatory signaling
pathways, which promote oxidative stress, chronic vascular
inflammation, endothelial dysfunction, and accelerated car-
diovascular aging in this phenotype.24
Lifestyle link. AT phenotype can be modified upon lifestyle
interventions. Physical exercise,9 intermittent fasting,25,26 diet
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quality,9 and regular circadian rhythms/restorative sleep18
promote the preservation of a healthy AT phenotype and
have the potential to reverse AT dysfunction and related
cardiometabolic risk. These effects occur largely indepen-
dent of body mass index (BMI).9,16 The CENTRAL-MRI
trial demonstrated that in a group of 278 sedentary adults
(age = 48 years, 89% men, BMI 30.8 kg/m2) with abdomi-
nal obesity (75%) or dyslipidemia, a Mediterranean low-
carbohydrate dietary pattern was superior to a low-fat diet in
decreasing intrahepatic, intrapericardial, and pancreatic fat
(P < 0.05 for all), and that exercise had an independent
contribution to visceral AT loss.27 Further to that, mobili-
zation of ectopic fat depots was associated with improved
cardiometabolic surrogate markers such as decreased ex-
pression of atherogenic dyslipidemia.27,28
Skeletal muscle secretome. Upon contraction, skeletal mus-
cle fibers express and release cytokines and other peptides,
which encompass a group of hormone-like substances re-
ferred to as myokines.12 Myokines exert their effects within
the muscle itself (autocrine and paracrine function) and in-
teract with remote tissues and organs (endocrine function).
The muscle secretome consists of several hundred myokines
that communicate with other organs, such as AT, liver, pan-
creas, vasculature, immune system, bones, and brain12
(Fig. 1B). Myokines such as irisin, fibroblast growth factor
21, interleukin (IL)-6, and IL-15 can improve cardiometa-
bolic health through several mechanisms: (1) AT browning
and maintenance of a functional white AT phenotype, (2)
preservation of muscle mass, (3) improved endothelial func-
tion and myocardial contractility, (4) decreased inflamma-
tion, and (5) improved metabolic status, including increased
insulin sensitivity and glucose homeostasis.11,12,16 This un-
derpins the importance of maintaining or increasing muscle
mass to attenuate cardiovascular aging.
Nonresolving inflammation and plaque phenotype
Inflammatory processes at the endothelial layer of the
arterial wall play a fundamental role in the initiation, pro-
gression, and in particular, the clinical complications of
FIG. 1. The ectopic adiposity phenotype. Ectopic fat accumulation in the abdominal cavity (visceral fat) and in organs
like pericardium, liver, and pancreas (A), and muscle wasting/intramuscular fat accumulation (B) are bidirectionally linked
to chronic inflammation (C) and insulin resistance (D), both of which have been linked to conventional and novel pathways
of cardiometabolic risk.9 Ectopic fat is a major driver of atherosclerosis and its acute complications: epicardial fat (A1) has
been linked to AF, accelerated coronary atherosclerosis, and left ventricular diastolic dysfunction20; hepatic fat (NAFLD)
(A2) causally contributes to atherogenic dyslipidemia and is closely linked to subclinical atherosclerosis22; and pancreatic
fat (A3) has been linked to beta-cell dysfunction23 and concomitant postprandial and fasting hyperglycemia. Chronically
elevated serum glucose levels, and postprandial glucose spikes in particular, promote oxidative stress/chronic inflammation,
endothelial dysfunction, and sympathetic hyperactivity, and result in the formation of AGEs. Glycation damage has been
pathophysiologically linked to numerous chronic disease states such as cardiovascular aging.24 Down arrows indicate
decreased levels, and up arrows indicate increased levels. AF, arrhythmia/atrial fibrillation; AGEs, advanced glycation end
products; NAFLD, non-alcoholic fatty liver disease. Color images are available online.
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high-risk atherosclerosis. The acute inflammatory response
is divided into the two phases of initiation and resolution.29
Mounting evidence points to defects in inflammation reso-
lution as a key causal factor in atherosclerosis (Fig. 1C).
During the initiation phase, apolipoprotein B-containing
lipoproteins, when retained and modified (oxidized) in the
subendothelial vascular wall, serve as damage-associated
molecular patterns (DAMPs). DAMPs activate cytokine syn-
thesis through pattern recognition receptors, for example,
TLRs.30 Activation of TLR2 and the NLRP3-inflammasome
by apolipoprotein C3 (ApoC3) provides one link between
atherogenic lipoprotein patterns as seen in MetS and im-
mune activation/inflammation. It is furthermore worth not-
ing that certain saturated fatty acids (SFA) such as palmitic
acid (C16:0) promote TLR activation.21,31 In the ectopic
adiposity phenotype, excess dietary starch, sugar, and pro-
tein are converted into fatty acids (FA)—in particular pal-
mitic acid (C16:0)—during a metabolic process referred to
as hepatic de novo lipogenesis.14,31 This is another mecha-
nism by which proinflammatory signaling pathways are
activated in the phenotype with ectopic adiposity and
NAFLD in particular. Inflammasome activation within
macrophages leads to the release of proinflammatory cyto-
kines, such as IL-1b, which are chemotactic for other in-
flammatory cells; this includes T cells and B cells, which
further sustain the chronic inflammatory response by ex-
pression of proinflammatory cytokines and eicosanoids.29,30
During the resolution phase, in a process referred to as
efferocytosis, biosynthesis of proinflammatory mediators
(e.g., leukotrienes) transitions to synthesis of specialized
proresolving mediators (SPMs).29 Efferocytosis—the phago-
cytic removal of apoptotic cells—is a crucial step in the
resolution of lesional inflammation in chronic nonresolving
inflammatory diseases.29 A mismatch between SPMs (low)
and proinflammatory lipids such as leukotrienes (high)
results in efferocytosis failure, which is, in large part,
mediated by a shift in macrophage phenotype from the anti-
inflammatory M2-like to proinflammatory M1-like macro-
phages.32 SPMs, which are predominantly produced by M2
macrophages during efferocytosis, include lipoxins bio-
synthesized from arachidonic acid and E-series resolvins
from the eicosapentaenoic acid (EPA) and docosahexaenoic
acid (DHA)-derived D-series resolvins, protectins, and
maresins.33 These anti-inflammatory mediators support ef-
ferocytosis by (1) limiting further neutrophil granulocyte
recruitment to the site of injury and (2) enhancing macro-
phage uptake of cellular debris and apoptotic neutrophil
granulocytes.33 One subgroup of maresins is involved in
switching macrophage phenotype from the proinflammatory/
proatherogenic M1 to the anti-inflammatory/antiatherogenic
M2 phenotype.33 Failure to clear apoptotic cells from ath-
erosclerotic plaques results in secondary necrosis, which
generates inflammation owing to the release of DAMPs
from necrotic cells.29
Lifestyle link. One group of SPMs that supports resolu-
tion of inflammation are derivatives of the long-chain ma-
rine n-3 fatty acids EPA and DHA.32 It is furthermore worth
noting that DHA inhibits TLR2/4 dimerization and activa-
tion. TLRs—as discussed above—are pattern recognition
receptors that can be activated by both pathogen-associated
molecular patterns and nonmicrobial endogenous molecules.
The inhibition of TLR2/4 dimerization and activation by
DHA suggest a role for dietary components to modulate
TLR-mediated immune responses.21 EPA and DHA can
be supplemented or obtained by the consumption of
oily fish.
In an inflammatory resolving environment, vascular smooth
muscle cells that migrate from the medial layer undergo a
phenotypic shift, forming a collagenous fibrous cap that over-
lies the lipid-rich plaque core. Plaque with net resolution is
smaller, has a thicker fibrous cap (with predominantly anti-
inflammatory M2-like macrophages, smooth muscle cells, and
intact collagen), and has a smaller necrotic lipid core.32
In the setting of continued inflammation, advanced lesions
develop. They are larger, have a thinner fibrous cap (with
predominantly proinflammatory M1-like macrophages, few
smooth muscle cells, and cleaved collagen), and have a
larger necrotic lipid core.32 Cells in advanced atherosclerotic
plaques express a senescence-associated secretory pheno-
type, producing metalloproteinases that degrade the extra-
cellular matrix, which promotes inflammation, while further
weakening the fibrous cap, thus fostering a milieu conducive
for a vulnerable plaque phenotype.19,29 This is commonly
referred to as thin-cap fibroatheroma (TCFA) (reviewed in
Kasikara et al.29, and Bäck et al.32) (Fig. 1E). One indica-
tor for the presence of TCFA, and concomitant vascular
inflammation, is lipoprotein-associated phospholipase A2
(Lp-PLA2), which plays a key role in the degradation of
proinflammatory oxidized phospholipids to generate lyso-
phosphatidylcholine (Lyso-PC) and oxidized fatty acids,34 as
depicted in Figure 2. It is, however, important to note that,
while Lp-PLA2 activity is a marker of risk, pharmacologi-
cal lowering of Lp-PLA2 in patients with stable coronary
heart disease (CHD) has not been shown to reduce clinical
cardiovascular endpoints.35
Longitudinal observational studies have demonstrated
that elevated blood levels of proinflammatory biomarkers,
including high-sensitivity C-reactive protein (hsCRP) and
IL-6, predict the risk of ASCVD.36 Proof of principle that
lowering inflammation with pharmacotherapy reduces car-
diovascular events in the absence of lipid lowering came
from the Canakinumab Anti-inflammatory Thrombosis Out-
comes Study (CANTOS). In CANTOS, treatment with ca-
nakinumab, a human monoclonal antibody directed against
the proinflammatory cytokine IL-1b, significantly reduced
IL-1b, IL-6, and hsCRP and demonstrated a cardiovascular
(CV) benefit.37,38 Unlike CANTOS, the Cardiovascular In-
flammation Reduction Trial (CIRT), which tested low-dose
methotrexate among patients with established CAD and di-
abetes and/or MetS, did not reduce IL-1b, IL-6, or C-reactive
protein (CRP), and did not result in fewer cardiovascular
events compared with placebo.39
Collectively, the evidence from CANTOS and CIRT
suggests that the prognostic value of anti-inflammatory
agents might strongly depend on the inflammatory pathway
targeted. While inhibition of IL-1b and IL-6-signaling,
which are initiated at the level of the NLRP3 inflammasome,40
effectively reduced cardiovascular events in CANTOS—
with human genetic data implicating these pathways as
causal in atherothrombosis40—a treatment not targeting the
IL-1b and IL-6-signaling pathway (i.e., CIRT) failed to
show prognostic benefit.
Lifestyle link. As further development and evaluation of
pharmacological agents targeting IL-6, IL-1b, and the
NLRP3 inflammasome are under way, possible alternative
strategies to support resolution of inflammation to lower risk
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of cardiovascular disease (CVD) are (1) to increase the
precursors of SPMs through dietary supplementation of
the marine n-3 fatty acids EPA and/or DHA19,29 and/or (2)
to address chronic inflammation by lifestyle intervention.41
Vigorous physical activity, intermittent caloric restriction,
and carbohydrate restriction can be anti-inflammatory due to
elevations of the ketone b-hydroxybutyrate, an endogenous
inhibitor of the NLRP3 inflammasome.42 Furthermore,
contracting muscle secretes hormone-like substances termed
myokines, which have the potential to attenuate immuno-
senescence through altered tissue crosstalk.43 These effects
occur largely independent of body weight.
Insulin resistance/compensatory
hyperinsulinemia/prediabetes and diabetes
Insulin resistance is the inability of target tissues to co-
ordinate a normal glucose-lowering response at a normal
plasma insulin level, an effect involving suppression of
endogenous glucose production, suppression of lipolysis,
cellular uptake of available plasma glucose, and net glyco-
gen synthesis.44 Compensatory hyperinsulinemia is the con-
sequence of insulin resistance. It means that when insulin
resistance is present, fasting and postprandial plasma insulin
levels stay chronically elevated and increase further fol-
lowing a glycemic load.44 This chronic state of exaggerated
postprandial dysmetabolism, including elevated plasma in-
sulin – glucose and free fatty acids, creates a milieu con-
ducive to the development of high-risk atherosclerosis and
type 2 diabetes mellitus (T2DM), one of the major risk
factors for ASCVD.45
As depicted in Figure 1, impaired insulin signaling affects
processes in various tissues and organs relevant to ASCVD,
including dysregulation of glucose and lipoprotein metab-
olism and ectopic fat accumulation44 (Fig. 1A1–A3). Ad-
ditional features that have been associated with insulin
FIG. 2. Inflammation and plaque phenotype. When LDLs penetrate the intima of the vessel wall from the lumen, the Lp-
PLA2 residing there uses oxLDL as a substrate, hydrolyzing it to Lyso-PC and OxFA.34 Lyso-PC and OxFA act as
secondary messengers that stimulate the upregulation of adhesion molecules on the lumen surface, act as chemoattractants
for circulating inflammatory cells, and play a role in the activation and transformation of local macrophages within the
plaque lesion. As activated local macrophages take up oxidized (phospho)lipids, they transform to foam cells and subse-
quently express more Lp-PLA2, creating a vicious proinflammatory cycle. The expression of other cytokines like MCP-1
and adhesion molecules creates a feedback loop by attracting more monocytes to the plaque. This feedback loop generates a
vicious cycle of attracting more inflammatory cells to the plaque lesion, resulting in an infiltration with an abundance
of inflammatory cells, a thinning of the fibrous cap, and a growing necrotic lipid core. Although this process often results
in limited luminal narrowing, it leads to the main clinical complications of ASCVD.29 ASCVD, atherosclerotic cardio-
vascular disease; LDL, low-density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2; Lyso-PC, lyso-
phosphatidylcholine; MCP-1, monocyte chemoattractant protein-1; OxFA, oxidized fatty acids; oxLDL, oxidized LDL.
Color images are available online.
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resistance include inflammation/oxidative stress and in-
flammasome activation as discussed above46 (Fig. 1C),
procoagulation/impaired fibrinolysis (Fig. 1F), and endo-
thelial dysfunction (Fig. 1G).47 The procoagulatory state
associated with diabetes has been linked to higher concen-
trations of plasminogen activator inhibitor-1, which reflects
a state of fibrinolytic dysfunction in this phenotype. This
provides biological plausibility for the increased predis-
position of individuals with MetS to develop athero-
thrombosis.48,49 Endothelial dysfunction, a key antecedent
of age-related CVD risk, is attributed to selective vascular
insulin resistance, increased superoxide-related oxidative
stress, and inflammation mediated by, for example,
ApoC3.30 Endothelial dysfunction results in decreased bio-
availability of the vascular protective vasodilatory mole-
cule nitric oxide.47 Furthermore, hyperinsulinemia affects
kidney function in a way that promotes uric acid and sodium
retention and hypertension.50
T2DM constitutes the tip of the iceberg of this vicious
cycle of insulin resistance and compensatory hyperinsulin-
emia. It represents a model for accelerated cardiovascular
aging and leads to a substantial increase in risk for ASCVD,
the leading cause of death in people with T2DM.45 In this
regard, it should, however, be noted that insulin resistance
and compensatory hyperinsulinemia have been linked to the
pathogenesis of CHD and cardiometabolic endpoints even in
the absence of diabetes mellitus.51,52
Lifestyle link. Numerous lifestyle factors, dietary and
nondietary, negatively affect insulin sensitivity.41 En-
couragingly, insulin resistance and compensatory hyper-
insulinemia, even in overt T2DM, are reversible upon
reduction of intrahepatic, intrapancreatic, and intramuscular
fat storage pools as a result of dietary modification and in-
creased physical activity.23,27,53,54
Lipoprotein metabolism
LDL-C, the concentration in plasma of cholesterol in
LDL particles (LDL-P), is related exponentially to risk of
ASCVD, and lowering levels pharmacologically has been
shown to reduce the risk of cardiovascular events propor-
tional to the magnitude of LDL-C reduction in numerous
clinical trials. As a result of these relationships, LDL-C
reduction has been the cornerstone of ASCVD prevention
for decades.8 However, as described below, the LDL-C-
centric concept does not adequately represent the spectrum
of risk attributable to atherogenic lipoproteins.8,55
Atherogenic dyslipidemia/atherogenic lipoprotein phenotype in
MetS. The lipoprotein pattern referred to as atherogenic
dyslipidemia is the central lipoprotein phenotype associ-
ated with MetS, insulin resistance, T2DM, and visceral adi-
posity56,57 (Fig. 1A2). Both clinically and pathologically, it
closely tracks with high-risk atherosclerosis and ASCVD.57,58
Atherogenic dyslipidemia encompasses a constellation of
lipoprotein abnormalities, including high serum triglycer-
ides and low HDL-C [mainly due to reduced large HDL
particles (HDL-P)], as well as an atherogenic lipoprotein
phenotype, including a predominance of small, cholesterol-
depleted LDL-P, and an accumulation of triglyceride-rich
remnant lipoproteins.59,60 As opposed to elevated apoB (the
structural protein of all potentially atherogenic particles,
including VLDL, intermediate-density lipoproteins [IDL],
and LDL), levels of LDL-C are often not increased in this
syndrome. This discordance can result in significant un-
derestimation of ASCVD risk by reliance on LDL-C, and
failure to adequately manage this risk in individuals with
atherogenic dyslipidemia, and, more broadly, those with
visceral adiposity and other features of MetS [5–7].
Pathophysiologically, the sequence of lipoprotein
changes in atherogenic dyslipidemia is induced primarily by
abnormalities of hepatic fat metabolism. Increased rates of
de novo lipogenesis lead to an increased hepatic triglyceride
pool and overproduction of large, triglyceride-enriched
VLDL-P. The accumulation of these particles in plasma
results in the formation of increased levels of lipolytic
remnants and ultimately smaller LDL-P, as well as de-
creased HDL-C due to increased HDL-P catabolism.59 The
consequences with respect to the initiation and progression
of high-risk atherosclerosis are twofold. First, the presence
of small LDL-P in atherogenic dyslipidemia contributes to
a greater total number of circulating LDL-P, even when
LDL-C is normal or low. Second, there is clinically relevant
evidence that small LDL-P have properties that may render
them more pathologic per se.61–63 Mechanistically, this has
been linked to a longer residence time of small LDL-P in the
circulation due to reduced receptor-mediated clearance,
which exposes the endothelial lining to proinflammatory
and proatherogenic particle components such as ApoC3.30,55
This concept is supported by the notion that a common
underlying trait connecting lipoprotein metabolism to heart
disease risk is the extent to which the condition influences
the duration of exposure to arterial tissue, due to either the
properties of the LDL-P (e.g., small LDL) or to reduced
hepatic LDL receptor expression (e.g., in familial hypercho-
lesterolemia). Further traits that have been associated with
potentially higher atherogenicity of small LDL-P include
compositional and conformational changes that render them
more prone to retention,64 aggregation,65,66 and oxidation64 in
the arterial wall. Overall, there is not incontrovertible evi-
dence supporting the concept that particle for particle, a small
LDL-P (<25nm) is more atherogenic than a large LDL-P.
However, biological plausibility as well as clinical evidence,
as described below, justifies consideration of small LDL-P as
an informative marker of CVD risk in MetS.67
A number of studies have addressed the question as to
whether the measurement of larger versus smaller LDL-P
adds incremental information to standard lipid measure-
ments with respect to cardiovascular outcomes. In the
Quebec Cardiovascular Study, levels of small LDL-P were
independently associated with CHD risk in 2072 men over a
13-year follow-up; in contrast, large LDL-P had no pre-
dictive value.62 In line with these data, two prospective
analyses from the Atherosclerosis Risk in Communities
(ARIC) and the Multi-ethnic Study of Atherosclerosis
(MESA) cohorts showed a progressive increase in CHD risk
over quartiles of small dense LDL cholesterol (sdLDL-C)
levels. In line with the results from the Quebec Cardiovas-
cular Study, there was no relationship with large LDL-P.61,68
In the ARIC study, among 11,419 men and women during a
mean follow-up of about 11 years, sdLDL-C was signifi-
cantly associated with incident CHD after adjusting for
standard nonlipid CHD risk factors even in individuals with
LDL-C levels <100mg/dL.61 Similarly, in 4387 normogly-
cemic individuals in the MESA cohort followed for a mean
of 8.5 years, elevated sdLDL-C was a risk factor for devel-
oping CHD after adjusting for standard CHD risk factors,
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triglycerides, and HDL-C.68 Collectively, these data support
the concept of greater atherogenic risk associated with
smaller versus larger LDL-P.
In patients living with MetS, sdLDL particles are strong
predictors of cardiovascular and cerebrovascular events
beyond traditional cardiovascular risk factors.69 In this sub-
group, improving the quality of lipoproteins may represent
an independent target to reduce cardiovascular risk beyond
lowering the quantity of lipoproteins.70
Lifestyle link. Notably, levels of small LDL-P are pri-
marily responsive to dietary carbohydrate intake (increase
with higher carbohydrate consumption), while large LDL-P
are more responsive to dietary saturated fat (increase with
higher saturated fat consumption). Both weight loss and
carbohydrate restriction decrease the expression of the
small LDL-P pathway.71 These considerations provide some
biological plausibility for the observation that in large
populations, higher dietary saturated fat consumption is
associated with higher LDL-C, but not with higher all-cause
or CVD mortality.72 LDL-C might thus provide misleading
information as to the effect of diet on ASCVD risk and
may therefore be an inappropriate marker for informing
dietary advice.73,74 A further level of complexity regarding
recommendations for dietary fat intake is the fact that die-
tary fats comprise heterogeneous molecules with diverse
structures even within conventional fat classes (i.e., satu-
rated, monounsaturated, and polyunsaturated fatty acids).74
For example, odd-chain SFAs (C15:0 and C17:0) are rela-
tively unique to dairy fat, are not synthesized by humans,
and are therefore regarded as reasonable biomarkers of
dairy fat consumption. Cohort studies measuring these
biomarkers of dairy fat intake show associations with pro-
tection against diabetes, and meta-analytic evidence from
prospective studies suggest that C17:0, but not C15:0, intake
is inversely associated with the risk of CVD.74 Collectively,
this does not speak to restricting all food sources of dietary
saturated fat for cardiometabolic health and supports food-
based, instead of nutrient-based dietary recommendations.73
HDL-C and HDL subclasses. While clinical and epide-
miological evidence have consistently shown an inverse
association between HDL-C levels and ASCVD,75,76 the
failure of clinical trials targeting HDL-C to show prognostic
benefit,77 in conjunction with genetic evidence,78 supports
the notion that HDL-C is not causal in ASCVD. It is,
however, worth mentioning that features of HDL other
than its cholesterol content are of pathophysiological im-
portance, most notably, the capacity of its major apoprotein
component, apoAI, to promote cellular cholesterol efflux.79
While there is limited evidence that clinical measurement
of HDL size subclasses provides information bearing on
specific functional properties of HDL, it is of interest that
small HDL-P have recently been reported to be associated
with increased coronary plaque stability.80
Clinical assessment of ASCVD risk—beyond LDL-C
Lipid and lipoprotein measurements. As noted above, a
measurement derived from a standard lipid panel that is
more strongly related to ASCVD risk than LDL-C, partic-
ularly in patients with features of the ectopic fat phenotype,
is non-HDL-C (total cholesterol minus HDL-C), which
comprises the cholesterol content of VLDL and atherogenic
remnant lipoproteins, in addition to LDL.72 However, mea-
surements of plasma apoB5–7 and/or LDL-P subclasses55
provide more specific measures of atherogenic lipoprotein
burden that can also serve as guides for therapeutic man-
agement of ASCVD risk. In this regard, LDL-P subclass
analysis has the potential to detect atherogenic lipoprotein
patterns, which are below the discrimination level of stan-
dard lipid testing in MetS.60
Another metabolic index that can be derived from standard
laboratory assays is triglyceride to HDL-C (TG/HDL-C) ra-
tio, which is associated with both insulin resistance and
measures of atherogenic dyslipidemia, including smaller
LDL-P diameter (also designated LDL subclass phenotype
B)81 and higher remnant lipoprotein particle cholesterol.61
Furthermore, the TG/HDL-C ratio has been linked to plaque
phenotype and clinical stability in coronary artery disease:
the ratio was significantly higher in patients with TCFAs
than in those without, and it was nonsignificantly higher in
patients with multiple recurrent acute coronary syndromes
than in those with long-standing stable angina.82–84 Of note,
triglycerides and the TG/HDL-C ratio do not reliably pre-
dict insulin resistance in African Americans. This has been
linked to the observation that insulin resistance does not
impair lipoprotein lipase in this subgroup and thus does not
induce hypertriglyceridemia.85
Hypertriglyceridemic waist
At any given BMI, an elevated waist circumference is
predictive of visceral adiposity.13 Using waist circumfer-
ence as a proxy, increased ectopic and hepatic fat22 in
particular, is an independent risk factor for high-risk ath-
erosclerosis9,10 and coronary artery disease and death in
prospective studies.45 Mendelian randomization analyses
indicate that triglyceride-related risk is causal in ASCVD
and considering triglyceride levels along with waist cir-
cumference improves risk prediction.8,78 Hypertriglyceri-
demic waist, a visceral adiposity marker combining elevated
waist circumference (‡90 cm) and elevated fasting plasma
triglycerides (‡2mmol/L), thus has good diagnostic accu-
racy for the identification of individuals at high risk of
ASCVD.86
Lifestyle link. Adequate intake of EPA+DHA and/or EPA
only at doses of >3 and 4 g/day, respectively, is an effective
and safe option for lowering triglycerides87 and hepatic fat
content in NAFLD.41,88
Inflammatory markers
While CRP is not thought to have a causal role in ASCVD,
its measurement may augment overall ASCVD risk assess-
ment, as it is a downstream marker of the IL-1b–IL-6
pathway, for which there is evidence of causality.40 Thus,
measurement of high-sensitivity (hs) CRP may have a role
in assessing ASCVD risk in patients with features of MetS,
in whom other measurements are inconclusive.
Conclusions
While atherosclerosis is in large measure a lipoprotein-
driven disease, there are numerous factors that modify that
causality. In particular, in the setting of excess ectopic fat
accumulation, metabolic stress fosters a milieu conducive
for high-risk atherosclerosis and its clinical complications:
dysfunctional AT phenotype and secretome, chronic low-
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grade inflammation, atherogenic dyslipidemia, impaired fi-
brinolysis, and endothelial dysfunction.89 This combination
of high-risk metabolic and inflammatory traits can be in-
expensively detected by combining anthropometric mea-
sures and clinically available biomarker panels.
Authors’ Contributions
All authors listed have contributed sufficiently to the article
to be included as authors, and all those who are qualified to be
authors are listed in the author byline. K.L. did the literature
search, and drafted the article. N.K., C.v.S., N.W., U.N., B.L.,
J.S., and O.W. reviewed and edited the article. A.L.M. and
R.M.K contributed significantly to the writing process.
R.M.K. supervised the writing process and did major revi-
sions. All authors approved the final version of the article.
Acknowledgment
The authors are indebted to Nicola Bernhart for graphical
design.
Author Disclosure Statement
K.L., N.K., N.W., U.N., B.L., J.S., and O.W. declare
that no competing financial interests exist with respect to
this article. A.L.M. is employed by Virta Health and has
been offered stock options. C.v.S. operates Omegametrix, a
laboratory for fatty acid analyses. He consults for BASF/
Pronova, and Huntsworth Medical, and received speaker’s
honoraria from Abbott, DSM, and Norsan. R.M.K. is on the
Scientific Advisory Board of Virta Health and Day Two, has
grant support from Quest Diagnostics and Dairy Manage-
ment, Inc., and has a licensed patent for lipoprotein particle
analysis by ion mobility.
Funding Information
No funding was received for this article.
References
1. GBD 2015 Mortality and Causes of Death Collaborators.
Global, regional, and national life expectancy, all-cause
mortality, and cause-specific mortality for 249 causes of
death, 1980–2015: A systematic analysis for the Global
Burden of Disease Study 2015. Lancet 2016;388:1459–
1544.
2. Davidson MH, Ballantyne CM, Jacobson TA, et al. Clinical
utility of inflammatory markers and advanced lipoprotein
testing: Advice from an expert panel of lipid specialists.
J Clin Lipidol 2011;5:338–367.
3. Mora S, Martin Seth S, Virani Salim S. Cholesterol insights
and controversies from the UK Biobank Study. Circulation
2019;140:553–555.
4. Tabas I, Williams KJ, Boren J. Subendothelial lipoprotein
retention as the initiating process in atherosclerosis: Update
and therapeutic implications. Circulation 2007;116:1832–
1844.
5. Sniderman AD, Pencina M, Thanassoulis G. ApoB. Circ
Res 2019;124:1425–1427.
6. Sniderman AD, Toth PP, Thanassoulis G, et al. An
evidence-based analysis of the National Lipid Association
recommendations concerning non-HDL-C and apoB. J Clin
Lipidol 2016;10:1248–1258.
7. Sniderman AD, Thanassoulis G, Glavinovic T, et al.
Apolipoprotein B particles and cardiovascular disease: A
narrative review. JAMA Cardiol 2019 [Epub ahead of
print]; DOI: 10.1001/jamacardio.2019.3780.
8. Ganda OP, Bhatt DL, Mason RP, et al. Unmet need for
adjunctive dyslipidemia therapy in hypertriglyceridemia
management. J Am Coll Cardiol 2018;72:330–343.
9. Oikonomou EK, Antoniades C. The role of adipose tissue
in cardiovascular health and disease. Nat Rev Cardiol 2019;
16:83–99.
10. Shulman GI. Ectopic fat in insulin resistance, dyslipidemia,
and cardiometabolic disease. N Engl J Med 2014;371:
2237–2238.
11. Fiuza-Luces C, Santos-Lozano A, Joyner M, et al. Exercise
benefits in cardiovascular disease: Beyond attenuation of
traditional risk factors. Nat Rev Cardiol 2018;15:731–743.
12. Pedersen BK, Febbraio MA. Muscles, exercise and obesity:
Skeletal muscle as a secretory organ. Nat Rev Endocrinol
2012;8:457–465.
13. Despres JP. Body fat distribution and risk of cardiovascular
disease: An update. Circulation 2012;126:1301–1313.
14. Al-Mrabeh A, Zhyzhneuskaya SV, Peters C, et al. Hepatic
lipoprotein export and remission of human type 2 diabetes
after weight loss. Cell Metab 2019 [Epub ahead of print];
DOI: 10.1016/j.cmet.2019.11.018.
15. Chen GC, Arthur R, Iyengar NM, et al. Association be-
tween regional body fat and cardiovascular disease risk
among postmenopausal women with normal body mass
index. Eur Heart J 2019;40:2849–2855.
16. Priest C, Tontonoz P. Inter-organ cross-talk in metabolic
syndrome. Nat Metab 2019;1:1177–1188.
17. Wang Z, Wang D, Wang Y. Cigarette smoking and adipose
tissue: The emerging role in progression of atherosclerosis.
Mediators Inflamm 2017;2017:11.
18. Pagano ES, Spinedi E, Gagliardino JJ. White adipose tissue
and circadian rhythm dysfunctions in obesity: Pathogenesis
and available therapies. Neuroendocrinology 2017;104:
347–363.
19. Ferrucci L, Fabbri E. Inflammageing: Chronic inflamma-
tion in ageing, cardiovascular disease, and frailty. Nat Rev
Cardiol 2018;15:505–522.
20. Packer M. Epicardial adipose tissue may mediate deleteri-
ous effects of obesity and inflammation on the myocar-
dium. J Am Coll Cardiol 2018;71:2360–2372.
21. Hwang DH, Kim JA, Lee JY. Mechanisms for the activa-
tion of Toll-like receptor 2/4 by saturated fatty acids and
inhibition by docosahexaenoic acid. Eur J Pharmacol
2016;785:24–35.
22. Stahl EP, Dhindsa DS, Lee SK, et al. Nonalcoholic fatty
liver disease and the heart. J Am Coll Cardiol 2019;73:948.
23. White MG, Shaw JA, Taylor R. Type 2 diabetes: The
pathologic basis of reversible beta-cell dysfunction. Dia-
betes Care 2016;39:2080–2088.
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